- IMUNON (IMNN, Financial) will publish findings from its Phase 1/2 OVATION 2 trial on June 3, 2025, in the journal Gynecologic Oncology.
- The study examines the efficacy of intraperitoneal IMNN-001 combined with chemotherapy in advanced epithelial ovarian cancer patients.
- The data will also be presented at the 2025 ASCO Annual Meeting in Chicago.
IMUNON, Inc. (IMNN), a clinical-stage biotechnology company, has announced the publication of data from its Phase 1/2 OVATION 2 trial in the esteemed journal Gynecologic Oncology, scheduled for June 3, 2025. This trial evaluates the novel DNA-mediated immunotherapy, IMNN-001, administered intraperitoneally in combination with neoadjuvant and adjuvant chemotherapy in patients with newly diagnosed advanced epithelial ovarian cancer.
The company disclosed that these findings will also be shared through an oral presentation at the 2025 Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago. Led by Dr. Premal H. Thaker of the Washington University School of Medicine, this presentation underscores the critical need for innovative therapeutic approaches in ovarian cancer treatment, emphasizing the potential of IMUNON’s TheraPlas® platform technology.
The OVATION 2 trial examined the safety and efficacy of IMNN-001 in combination with standard chemotherapy agents, paclitaxel and carboplatin, across 112 patients. The study focused on tumor reduction prior to surgery and aimed to increase survival rates among those with advanced-stage disease, which often suffers high recurrence rates after traditional treatment.
IMUNON’s approach, leveraging the TheraPlas® platform, offers a promising avenue in cancer immunotherapy by instructing the body to produce anticancer proteins locally. This aims to harness the immune system's natural defenses, potentially improving outcomes for patients.
